ang-3777
Small moleculeexperimental
Clinical trial activity
9 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01286727)
Timeline
Indications
Mechanism of action
MET agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hepatocyte growth factor mimetic
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04958187 | Phase 1 | Jul 31, 2021 | Angion Biomedica Corp, Nucleus Network Ltd |
| NCT04898907 | Phase 1 | Jun 30, 2021 | Angion Biomedica Corp, Quotient |
| NCT04931524 | Phase 1 | May 21, 2021 | Angion Biomedica Corp, Quotient |
| NCT04459676 | Phase 2 | Jul 31, 2020 | Angion Biomedica Corp, CTI Clinical Trial and Consulting Services |
| NCT02771509 | Phase 2 | Dec 1, 2016 | Angion Biomedica Corp |
| NCT02474667 | Phase 3 | Jan 1, 2016 | Angion Biomedica Corp |
| NCT01539590 | Phase 2 | Jul 1, 2012 | Angion Biomedica Corp, National Heart, Lung, and Blood Institute (NHLBI), Sponsor GmbH |
| NCT01561599 | Phase 2 | Aug 1, 2011 | Angion Biomedica Corp, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT01286727 | Phase 2 | Feb 1, 2010 | Angion Biomedica Corp, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Sponsor GmbH |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Angion Biomedica Corp | For profit | 9 | 9 | 3 | 2010 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 2 | 0 | 1 | 2010 |
| Quotient | For profit | 2 | 0 | 1 | 2021 |
| Sponsor GmbH | Academic/Hospital | 2 | 0 | 1 | 2010 |
| CTI Clinical Trial and Consulting Services | For profit | 1 | 0 | 1 | 2020 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2012 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1